Source: Annual Congress 2002 - Asthma: Inflammation, hyperreactivity, treatment side effects



Rating:

Share or cite this content

Citations should be made in the following way:
P. Cremaschi, C. Catanese, G. Terzuolo, S. Rizzo, O. Filieri, A. Rossi (Pavia, Italy). Recurrent eosinophilic pneumonia in an asthmatic patient treated with sequential montelukast/zafirlukast after corticosteroid withdrawal. Eur Respir J 2002; 20: Suppl. 38, 435

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia Source: Eur Respir J 2015; 45: 1624-1631 Year: 2015 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Source: Eur Respir J 2003; 22: 8-13 Year: 2003 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia Source: Eur Respir J 2013; 41: 402-409 Year: 2013 Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 707s Year: 2004 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Different treatment courses with inhaled corticosteroids for eosinophilic bronchitis Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 Clinical implication of interleukin-33 in acute eosinophilic pneumonia compared with chronic eosinophilic pneumonia Source: Annual Congress 2011 - Biomarkers of allergic inflammation Year: 2011 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021